PROSPER WEEKLY

CPA senior economist Mihir Torsekar and Andrew Rechenberg are back in action with new weekly episodes of The Big 3!  This week, the hosts examine how China’s economic playbook is reshaping U.S. trade, innovation, and national security—often with American firms’ help. The conversation opens with a deep dive into the $53 billion in licensing deals U.S. pharmaceutical companies have signed with Chinese biotech firms since 2020, effectively shifting early-stage drug innovation overseas and hollowing out U.S. research hubs. As China moved from dominating pharmaceutical manufacturing and APIs into biotech research, CPA economists Mihir and Andrew warn that speed and cost advantages come with serious risks, including unreliable data, homogenous clinical trials, and forced technology transfer.